Role of Lung Function for Exercise Capacity in Well-trained Individuals
NCT ID: NCT06077019
Last Updated: 2025-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2023-10-03
2026-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
U-LABA/ICS Effects on Exercise Performance, Vilanterol
NCT06066606
Effects of Inhaled Corticosteroids in the Systemic Inflammation Induced by Exercise in Patients With COPD
NCT02209974
U-LABA/ICS Effects on Exercise Performance, Formoterol
NCT06105671
Budesonide / Formoterol in Treatment of Exacerbations of COPD
NCT00239278
Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation
NCT00578968
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vilanterol
Participants inhale vilanterol + fluticasone furoat
Vilanterol and Fluticasone Furoate
Participants inhale 25 µg vilanterol + fluticasone furoate daily
Indacaterol
Participants inhale indacaterol + mometasone furoate
Indacaterol and Mometasone Furoate
Participants inhale 125 µg indacaterol + mometasone furoate daily
Placebo
Participants inhale placebo
Placebo
Participants inhale placebo daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vilanterol and Fluticasone Furoate
Participants inhale 25 µg vilanterol + fluticasone furoate daily
Indacaterol and Mometasone Furoate
Participants inhale 125 µg indacaterol + mometasone furoate daily
Placebo
Participants inhale placebo daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physically active \> 5 h weekly
* Maximal oxygen consumption classified as high or very high
Exclusion Criteria
* ECG abnormality
* ACQ score \> 1.5
* Severe bronchial hyperreactivity as determined by mannitol test
* FEV1/FVC ratio \< 0.7 determined with spirometry
* Chronic illness determined to be a potential risk for participant during study
* In chronic treatment with medication that may interfere with study results
* Pregnancy
* Smoker
* Blood donation during the past 3 months
18 Years
39 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Morten Hostrup, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Hostrup, PhD
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Morten Hostrup, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
August Krogh Building
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Morten Hostrup, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHRON_INDAC_VIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.